Protein phosphorylation is a key post-translational modification regulating protein function in almost all cellular processes. Although tens of thousands of phosphorylation sites have been identified in human cells, approaches to determine the functional importance of each phosphosite are lacking. Here, we manually curated 112 datasets of phospho-enriched proteins, generated from 104 different human cell types or tissues. We re-analyzed the 6,801 proteomics experiments that passed our quality control criteria, creating a reference phosphoproteome containing 119,809 human phosphosites. To prioritize functional sites, we used machine learning to identify 59 features indicative of proteomic, structural, regulatory or evolutionary relevance and integrate them into a single functional score. Our approach identifies regulatory phosphosites across different molecular mechanisms, processes and diseases, and reveals genetic susceptibilities at a genomic scale. Several regulatory phosphosites were experimentally validated, including identifying a role in neuronal differentiation for phosphosites in SMARCC2, a member of the SWI/SNF chromatin-remodeling complex.
P rotein phosphorylation is a post-translational modification (PTM) involved in the regulation of most biological processes and its misregulation has been linked to several human diseases 1, 2 . The full extent of human phosphorylation is still an open question under active investigation through mass spectrometry (MS) approaches 3 . Notably, an in-depth study of a single cell line identified over 50,000 phosphopeptides and suggested that 75% of the proteome may be phosphorylated 4 . The aggregation of such studies has led to the identification of over 200,000 phosphosites in resources such as PhosphoSitePlus (PSP) 5 .
Although analytical challenges remain, the bottleneck in the study of phosphorylation is shifting toward its functional characterization 6 . Given that phosphorylation can be poorly conserved, it has been suggested that not all phosphorylation is relevant for fitness [7] [8] [9] . Therefore, prioritization strategies are crucial to facilitate the discovery of highly relevant phosphosites 10 . Different methodologies have been proposed, including identifying phosphosites that are highly conserved 11, 12 , are located at interface positions [13] [14] [15] and show strong regulation, or combinations of such features 10, 16 . Mutational studies have also been used to characterize relevant phosphorylations 17 , but cannot yet be applied to human phosphorylation at scale.
Machine learning methods remain a poorly explored approach to study the functional relevance of phosphorylation. Here, we generated the largest human phosphoproteome dataset to date, identifying 119,809 human phosphosites. For each phosphosite, we compiled annotations covering 59 features and integrated them into a single score of functional relevance, named here as the phosphosite functional score. This score can correctly identify regulatory phosphosites for a diverse set of mechanisms and predict the impact of deleterious mutations.
Results
Mass spectrometry-based proteomics map of the human phosphoproteome. To create a comprehensive MS-based definition of the human phosphoproteome, we curated 112 human public phospho-enriched datasets derived from 104 different cell types and/or tissues from the PRIDE database 18 ( Supplementary Table 1 ). Using MaxQuant (MQ), we jointly reanalyzed the subset of 6,801 human MS experiments passing the quality control criteria, corresponding to 575 d of accumulated instrument time 19 (Methods) . The joint analysis (deposited in PRIDE, dataset PXD012174) ensured adequate control of the false discovery rate (FDR) estimated using a target-decoy strategy 20 (Methods) . FDR was estimated for correct matching to the peptide-spectrum match (PSM), protein and the presence of phosphosite modification(s) and kept at <1% (Methods). The modification localization probability (also called the false localization rate) was also estimated, reflecting the confidence of pinpointing which residue carries the phosphorylation. Probabilities above 75% indicate high confidence localizations (class I sites).
We identified 11.7 million phosphorylated PSMs (PSM-level FDR <1%), corresponding to 181,774 phosphopeptides spanning 203,930 phosphorylated serines, threonines or tyrosines. Of these, only 119,809 sites passed the 1% site-level FDR correction (59% true positive sites), with 90,443 classified as class I (ref. 21 ). The low true positive percentage suggests that the accumulation of phosphosite identifications from multiple independent searches-as archived in phosphosite databases-might be strongly enriched for potential false positives. The heterogeneity of the analyzed biological samples facilitated the identification of phosphosites in proteins expressed in a wide range of tissues, from healthy and tumor samples ( Fig. 1a ), allowing us to identify a large number of tissue-specific phosphosites ( Fig. 1b) .
To evaluate the phosphoproteome coverage, we studied the proportion of phosphoproteins while stratifying them according to their abundance 22 . Of 14,154 proteins identified, 11,982 (85%) contained at least one FDR-corrected phosphosite. While we observed a bias toward the identification of more abundant proteins, the trend was similar to that of the unmodified peptides present in the samples (Fig. 1c ). This ratio of phosphoproteins, similarly to previous findings 4 , remained constant regardless of the reported protein abundance in PaxDb ( Supplementary Fig. 1 ). While some cell types, such as HeLa cells, were very over-represented, the identified phosphosites were not strongly biased by common samples. Exclusion of the five most studied cell types (31% of the total instrument time), still resulted in 83% of the total identified phosphosites ( Fig. 1d ). Together, these results suggest that we have achieved very high coverage of phosphosite identification.
For benchmarking purposes, we compared the identified phosphoproteome against the 221,236 human phosphosites reported by MS in the PSP database (January 2018) 5 (Fig. 1e ). While 11.5% of the high-confidence sites in our study were supported by only one piece of tandem mass spectrometry (MS/MS) evidence, 55%   PX  D0  00  83  6   PX  D0   00   45   1   PX   D0  00  24  2   PXD  001  180 PXD  0011  89 PXD00  2850 PXD001543 3 2 5 0 0 0 D X P PXD000089 PXD00 6475 PXD 001 253 PX D0 002 38 PX D0 00 75 0   PX D0 01 17 0  PX D 00 31 98 P X D 00 09 70 P X D 00 01 85 P X D 0 0 4 9 4 5 P X D 0 0 5 2 1 4 P X D 0 0 3 8 2 2 P X D 0 0 0 4 9 7 P X D 0 0 0 5 9 7 P X D 0 0 2 2 8 6 P X D 0 0 0 0 8 9 P X D 0 0 3 1 1 5 P X D 0 0 3 5 3 1 P X D 0 0 0 2 2 2 P X D 0 0 2 7 6 5 P X D 0 0 2 1 3 5 P X D 0 0 2 4 2 5 P X D 0 0 3 5 2 9 P X D 0 0 4 3 5 7 P X D 0 0 1 2 2 2 P X D 0 0 1 7 3 9 P X D 00 36 of the PSP sites had this level of support. In absolute numbers, we identified 73,973 phosphosites supported by five or more pieces of MS/MS evidence, while only 47,448 were equally supported in PSP. These results point to the importance of aggregating the growing body of MS phosphoproteomic data, while maintaining statistical reliability.
Prioritizing functional human phosphosites. Having identified a comprehensive high-confidence human phosphoproteome, we then calculated for every phosphosite a diverse set of features that could indicate the importance for fitness (Methods). These properties can be grouped broadly into four categories: MS evidence (for example, spectral counts and probability of localization); phosphosite regulation 23 , including the number of conditions in which the site is regulated or matching kinase motifs; the structural environment (for example, at interfaces and surface accessibility); and evolutionary conservation (Supplementary Note 1). Evolutionary conservation was captured by quantifying residue conservation 24 , conservation of the phosphorylation within protein domain families 11 and the phosphosite evolutionary age, expanding a phylogenetic-based approach previously described for fungal species to multicellular species 12 . Altogether, we calculated a set of 59 features annotating all phosphosites (Methods and Supplementary Table 2 ). We illustrate the value of some of these features for identifying regulatory sites in amino acids 65-80 of MAF1, a protein involved in the mTORC1 signaling pathway ( Fig. 2a ). While hosphorylation at S68 and S75 is known to inhibit the MAF1 RNA polymerase III repression function, three other MS-identified phosphosites in the region have unknown functional roles 25 . Relative to the other sites, pS68 and pS75 showed a higher number of spectral counts, higher conservation, a better match to the specificity of kinases and condition-specific regulation, including downregulation when cells were treated with the mTOR inhibitors rapamycin and Torin1. Benefiting from the orthogonal nature of some of these attributes, we next sought to integrate a set of 59 normalized features into a single score that would prioritize phosphosites relevant for fitness. We used 2,638 phosphosites curated by PSP and known to regulate protein function to discriminate, by machine learning the distinctive properties of functional serine/threonine and tyrosine phosphorylations, separately. We first asked how well each of the 59 features independently predicted the known regulatory sites (bars in Fig. 2b ). The most informative features for function included the number of different cell lines or tissues in which the site had been identified, the phosphosite age, how well the phosphosite matched a kinase specificity model, how often the phosphosite was regulated in a panel of different perturbations and the presence of neighboring PTMs.
Different machine learning algorithms were tested for their capacity to integrate the 59 features, with most methods displaying similar performance (Methods). The model selected was a gradientboosting machine that achieved an average area under the curve (AUC) of 86.1% and 85.7% for serine/threonine and tyrosine sites, respectively 26 . The contribution of the features included in the model denotes their relevance when combined with the rest of the features (Fig. 2b ). The performance of each individual feature in isolation and its contribution to the trained models are detailed in Supplementary  Table 2 . For example, consensus protein abundance increased in relevance when integrated with other features, indicating that it is not a useful predictor in isolation, but facilitates the interpretation of other features within the model. The integrated predictor displayed much higher performance than any of the features independently.
The final model-termed the phosphosite functional scorewas applied to generate a score for each of the MS-identified phosphosites, reflecting their importance for organismal fitness (Supplementary Table 3 ). In Fig. 2c , we show how this score ranked known functional phosphosites higher than the overall background, while more interestingly, phosphosites important for human disease-information not included in the model-ranked higher than the other two sets. Our metric very strongly outperforms generalpurpose tools such as variant effect predictors when estimating the relevance of functional and disease-associated phosphosites ( Supplementary Fig. 2 ). The functional score correctly distinguished relevant phosphosites across different protein families, as illustrated in four different examples, including the LCK kinase, the STAT3 transcription factor (TF), the PTPN11 phosphatase and the H2AFX histone ( Fig. 2d ). In all cases, the phosphosites of known function or associated with diseases were among the top ranked. An extensive literature search also pointed to highly scored phosphosites that, despite not being included in the true positive set derived from PSP, had supporting evidence of known regulatory function ( Supplementary Fig. 3 ).
Identifying functional phosphosites involved in diverse mechanisms. Phosphorylation modulates protein function via different molecular mechanisms. The distribution of phosphosite functional scores for annotated regulatory sites suggests that the method is not strongly biased toward specific mechanisms ( Supplementary Fig.  4 ). Next, we explored the potential of the functional score to prioritize regulatory functions related to protein-protein interactions and transcriptional activity.
The presence of a phosphosite at a protein interface, one of the used features, was interpreted as indicating that the phosphosite was likely to regulate protein-protein interactions (Methods and Supplementary Table 2 ). For example, the Y34 phosphosite in Ras homolog family member A had no annotated function in PSP but ranked as a highly functional site (0.56), partly owing to its presence in multiple interaction interfaces. Indeed, it has been reported that substitution of Y34 with asparagine 27 or phenylalanine 28, 29 can disrupt certain interactions ( Supplementary Fig. 5 ). To test broadly the value of the functional score for protein interactions, we compiled information on the consequences of mutations on measured protein interactions for 394 phosphosite positions 30 . We observed that phosphosites with a functional score higher than 0.5 had a five-to tenfold higher chance of a mutation causing changes in interactions ( Supplementary Fig. 6 ).
Independently, we sought to validate as a proof of principle, a candidate regulatory phosphosite in a protein interface. The PLK1regulated S60 was the best scoring phosphosite (0.65; Fig. 3a ) of RAN-binding protein 1 (RANBP1) 31 . This site is upregulated under okadaic acid and is near the Ran interaction interface and the transmembrane nuclear transporter Ran GTPase activating protein 1 ( Fig. 3b ; PDB 1K5G). To test the impact of pS60 on RanBP1 interactions, we performed an affinity purification experiment comparing the 3×FLAG-tagged wild type (WT) RANBP1 with RANBP1 S60E (Methods and Supplementary Table 4 ). The proteins RAN, RCC1 and NEMP1 were found among the top-scoring interactors. Binding of the phospho-mutant remained similar to that of WT in the case of RAN and RCC1, but the mutant showed a reproducible decrease (P < 0.003) in binding capability to NEMP1, an interaction partner previously described in other eukaryotes 32 (Fig. 3c ).
We next explored how phosphosite prioritization could be used to identify the sites implicated in the regulation of transcriptional activity. Changes in the activation state of TFs across different samples can be approximated by quantifying the changes in expression of their known target genes 33 . By analyzing 77 breast cancer samples where phosphorylation 34 and gene expression 35 data had been collected, we correlated the changes in phosphosite levels within TFs with changes in estimated TF activity (Methods). We exemplified this approach with phosphosites in STAT1 ( Fig. 3d) , where pS727 is necessary for full transcriptional activation 36 . We observed, as expected, that increased phosphorylation of S727 was associated with higher estimated TF activities ( Fig. 3e ). Across all STAT1 phosphosites, the functional score stratified all quantified sites on the basis of the correlation between the phosphorylation levels and the TF activity ( Fig. 3f ). We expanded this analysis to the 371 phosphosites in 82 TFs with available paired data and goodquality regulons. Although the set of sites with significant site-TF correlation was relatively small (19%), we observed that the functional score was able to prioritize sites in which the changes in phosphorylation strongly correlated with TF activity (Fig. 3g ).
Impact of genetic variation on highly functional phosphosites.
A functional phosphosite is expected to introduce a genetic constraint in the genome and highly functional phosphosites should therefore present a lower tolerance to variation. We analyzed available information on the allele frequency of variants in natural populations 37 (Fig. 4a ) and the clinical significance of mutations on human diseases 38 ( Fig. 4b and Methods). In both cases, we observed the expected constraint-mutations mapping to phosphosites with a high functional score were more likely to be rare in human populations ( Fig. 4a ) and pathogenic (Fig. 4b ). The annotated phosphoproteome provides an opportunity to further characterize the underlying mechanisms of disease-causing mutations. For example, the S172P substitution in tubulin beta 2B has been associated with polymicrogyria, a cortical developmental disease causing poor incorporation of tubulin into microtubules 39 . The finding of a highly functional phosphosite in S172 (0.43; Fig. 4b ) suggests that phosphoregulation is an important diseaserelated mechanism. Associating disease variants with the functionally annotated phosphoproteome can facilitate disease interpretation in a signaling context, expanding the possibility for diagnostic and therapeutic strategies. We provide the functional scores for ClinVar variants overlapping phosphorylation sites in Supplementary Table 5 .
The introduction of mutations in highly scored phosphosites is also expected to cause important functional consequences. 68 We curated information on protein gain and loss of function as a consequence of 1,092 mutations affecting phospho-acceptor residues (Methods and Fig. 4c ). In line with our expectation, the higher the functional score the higher the chance that a mutation had an effect (Fig. 4c) . Interestingly, substitutions of highly scored acceptors to alanine predominantly caused a loss of function, whereas a substitution to a negatively charged residue (creating a phosphomimetic) had an increased chance of causing a gain-offunction effect. To further expand on this idea, we studied two highly scored phosphosites of unknown function in glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The two sites, S151 and T153, flank the catalytic cysteine C152 in a highly conserved region (Fig. 4d ). Phosphorylation was consistently identified by MS, and the phosphosite functional scores (0.63 and 0.70, respectively) indicated a potential regulatory function (Fig. 4e) . We hypothesized that these phosphosites were important for the regulation of GAPDH activity and were functionally conserved between humans and yeast.
To test this hypothesis, we created two phospho-deficient strains in Saccharomyces cerevisiae by introducing mutations in the GAPDH gene (TDH3) disrupting S149 and T151, corresponding to S151A and T153A substitutions in human GAPDH. For these strains, we measured growth together with that of a TDH3 knockout (KO) strain in the presence and absence of the topoisomerase inhibitor doxorubicin (Methods). Deletion of TDH3 has been previously reported to cause slow growth under doxorubicin, a phenotype corroborated in our assay 40 . Interestingly, more acute growth defects were observed for the two phospho-deficient strains under doxorubicin (Fig. 4f,g) . TDH activity assays under no treatment pointed to depleted enzymatic activity of the two phosphodeficient strains (Fig. 4h ). The growth rate under doxorubicin and the enzyme activity of the point mutants were lower than for the KO strain, suggesting that the KO strain may have some compensation via TDH1 or TDH2 that is not seen in the strains carrying b, Mean functional score (confidence interval > 95%) for phosphosites at positions with mutations found in patients and having benign, uncertain or pathogenic consequences. The S172P substitution in tubulin beta 2B (TUBB2B) is highlighted as an example. c, Fold ratio of mutations mapping to phosphorylated positions reported in mutagenesis studies having gain-of-function or loss-of-function effects versus no effect and stratified by functional score. d, MS evidence for the phosphorylation of S151 and T153 in GAPDH and their structural context flanking a catalytic cysteine e, Position and functional score for all GAPDH phosphosites and alignment of two human phosphosites (S151 and T153) to corresponding S. cerevisiae TDH3 (S149 and T151). The color gradient corresponds to the supporting evidence of phosphorylation based on ancestral reconstruction. f,g, Consensus growth curves (f) and mean and s.e.m. of the AUC (g) for WT, control, GAPDH KO and S149 and T151 phospho-deficient mutants in the presence or absence of 75 µM doxorubicin. Every clone was present four times in each plate and the experiment was repeated three times for a total of 12 replicates. SC, synthetic complete. h, TDH3 activity as mean and s.e.m. measured twice in three independent extracts obtained from control and mutant strains.
the phospho-mutants. To gain insight into this difference we carried out a thermal proteome profiling experiment [41] [42] [43] comparing the thermal stability and abundance of 2,378 proteins between the mutant and WT strains (Methods and Supplementary Table 6 ). In unstressed conditions, there was higher abundance of the TDH2 protein in all three mutants (KO, S151A and T153A), which was more pronounced in the KO strain ( Supplementary Fig. 7 ). With doxorubicin, this increase was only significant in the KO strain ( Supplementary Fig. 7 and Supplementary Table 6 ). This increase in TDH2 may have partially compensated for the loss of TDH3 activity, which would explain the observed differences between the KO and the phospho-mutant strains. In addition, we measured no significant change in stability or abundance of TDH3 itself, indicating that the impact of the phosphosite mutations was not occurring via destabilization of the protein. Finally, we found significant enrichment for increased abundance of glycolytic proteins and increased stability of oxidative phosphorylation ( Supplementary Fig. 8 ), indicating that the decrease in activity of TDH3 results in substantial adaptation of metabolism.
Regulatory phosphosites in the human SWI/SNF remodeling complex member SMARCC2.
To further exemplify the usefulness of the functional score we studied regulatory sites governing the function of SMARCC2 (also known as BAF170) during neuronal differentiation. As part of the human SWI/SNF chromatin-remodeling complex, SMARCC2 plays an important role in neurogenesis 44, 45 . SMARCC2 expression increases during differentiation toward the commitment to neuronal precursors. Increased SMARCC2 replaces SMARCC1, composing the neural progenitor-specific SWI/SNF complex (or the npBAF complex) 46 . This switch recruits the REST (RE1-silencing transcription factor co-repressor) complex, an interaction that is important for neurogenesis 44 . We identified two highscoring phosphosites (S302 and S304) in SMARCC2 (Fig. 5a ) that we hypothesize could play an important regulatory function during neurogenesis.
To study the selected phosphosites, we used a murine model of neuronal differentiation and a gene knock-in system (Fig. 5b) . After verifying that the two phosphosites were identified by MS in mouse neuronal tissues 47 , we used CRISPR-based gene editing in mouse embryonic stem cells (ESCs) and independently generated three homozygous and two heterozygous clones of the double alanine mutant S302A/S304A, as well as control clones (with no mutation after CRISPR targeting). Neuronal differentiation was performed over 12 d, with an expected 44 increase of Smarcc2 measured by day 12 ( Supplementary Fig. 9 ), concurrent with post-mitotic neuron formation ( Supplementary Fig. 10 ). RNA sequencing (RNA-seq) was performed at days 8 and 12, corresponding to the differentiation to neuronal progenitor cells and post-mitotic neurons. When comparing mRNA levels using principal-component analysis (PCA; Fig. 5c ), the independent clones showed strong agreement with the major driver of change (PC1; Fig. 5c ) of time and the second major driver (PC2; Fig. 5c ) of mutational status. Two of three homozygous clones showed a clear separation from the heterozygous clones and CRISPR controls. A linear model identified 4,776 genes (P < 0.05) showing a difference in gene expression that was dependent on mutational status. This significant transcriptional difference is compatible with a change in the differentiation process as a consequence of the Smarcc2 alterations.
We noted that the homozygous mutants at day 12 displayed transcriptional similarities with all clones at day 8, suggesting a delay in differentiation. The homozygous mutants showed upregulation of gene signatures associated with murine pluripotency 48 and significant downregulation in neuronal differentiation signatures 49 (Fig. 5d ). In addition, known target genes of REST-a transcriptional repressor of neuronal genes-were significantly downregulated in the homozygous mutants, indicating maintained REST activity ( Fig. 5d ). Neuronal morphology also showed less differentiation in two homozygous clones at 12 d, with observed cell aggregates, fewer neurites and numerous Smarcc2-marked cells without a neuronal marker (for example, Map2; Fig. 5e ). Overall, these results point to a delay in differentiation in homozygous clones, suggesting that these phosphorylation sites play a role in the regulation of neuronal differentiation by SMARCC2.
Discussion
Benefiting from the vast amount of proteomics data deposited by the community in the PRIDE database, we generated a comprehensive human phosphoproteome. The large fraction of phosphosites identified, when excluding the most studied cell lines (for example, HeLa cells), highlights the high coverage achieved. However, some limitations need to be taken into consideration. The difficulties in detecting certain phosphopeptides-such as those in low-abundance proteins-or in accurately localizing phosphorylation events, point to a still incomplete phosphoproteome. Rarefaction curve analysis ( Supplementary Fig. 11 ) also suggests that we have not yet reached saturation of the number of identified sites, and the upper limit of phosphosites remains unknown. Our analysis also indicates that the inadequate aggregation of parallel MS searches can lead to a very substantial accumulation of false positives, which may be the case for public resources. Our priority has been to provide a highconfidence list of phosphosites, implying that some good-quality sites might not have made the final list owing to stringent criteria (Methods). The scale and level of curation of the spectral data analyzed (PRIDE dataset PXD012174) constitute an unprecedented resource to further develop new methods and strategies necessary to understand phosphoproteomics at large scale.
Although adequate methods were in place to prevent a biased scoring system, it is possible that the score may have been influenced by social bias to better characterize certain functional sites used for training, such as the tendency for researchers to study conserved positions. While we think such biases are possible, we do not think they dominate the score, as it could predict the impact of mutations in mapping to phosphorylated residues that were not part of the training. Although we have shown how highly scored phosphorylations are less likely to be mutated or more likely to be involved in disease processes, the full extent of this prioritization has not been explored. Disease variants on functional phosphosites could offer a mechanistic explanation for disease, possibly indicating a therapeutic strategy perhaps linked to an actionable regulatory kinase.
Despite the accuracy of the functional score, there were several phosphosites of known function that had a low functional score. When stratifying the functional phosphosites by their mechanisms of action ( Supplementary Fig. 3 ), we did not observe a strong difference. As a general trend, phosphosites that impact cellular localization, often overlapping short unstructured motifs, showed the lowest performance, and those regulating enzymatic activities and conformations, typically within ordered globular regions, showed the strongest performance. These trends, although not strong, may point to limitations in the current implementation of the method.
While we integrated a diverse set of features, additional ones may need to be considered in the future. These could include: measuring occupancy for a larger set of phosphosites 4 , acquiring diverse PTM datasets for different species, paired measurements of phosphoproteomics and protein localization 50 , and determining the structures of a larger set of phosphorylated proteins. Resolving structures of phosphoproteins has been technically very challenging, but recent developments in genetically encoded phosphorylation 50,51 should now serve as an opportunity to make progress in this area. Some of the current features may indirectly capture missing signals, such as how spectral counts relate to occupancy or the number of PTMs near a phosphosite relate to cross-regulation.
Together with the full list of human phosphosites and the spectral data released, the phosphosite functional score and the relevant features associated constitute a systematic resource to understand human signaling on a genomic scale. We have shown examples of how this information can prime the design of experiments to identify novel regulatory phosphosites. While some of the features may suggest a possible regulatory mechanism, such as the presence of phosphosites at interface positions, the functional score itself does not predict mechanisms. Moreover, the score might not accurately prioritize regulatory sites acting in groups, despite including features that capture local regulatory effects. Additional experimental and computational approaches need to be developed to study the biochemical consequences of individual and coordinated phosphorylations on a large scale.
Not all phosphorylations are likely to contribute equally to organismal fitness, and some have speculated that a fraction of phosphosites may serve no purpose in present-day species. Evolutionary studies have suggested that between 35% and 65% of sites are constrained and are therefore functional 9, 52 . Regardless of the degree of nonfunctional phosphorylation, there is a clear bottleneck in the characterization of phosphosite function that can be aided by the functional score. The different analyses provide guidance as to how to interpret and make use of the score. Scores above 0.5 were associated with a five-to tenfold increase in the chance of measuring an impact on interactions or phenotypes ( Fig. 4c and Supplementary Fig. 6 ). Similarly, pathogenic mutations had an average score of close to 0.5 compared to a score of around 0.2 for benign mutations (Fig. 4b) . At a 0.5 cutoff, around 10% of the phosphoproteome remains with 50% of the true positive phosphosites recovered, suggesting that this is a useful cutoff for an initial prioritization. The human phosphoproteome and functional score prioritization provided here define a roadmap to study the regulation of proteins involved in almost any cellular process.
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Methods
Human phosphoproteome MS search. A list of all 307 human datasets annotated to contain phosphorylations was retrieved from the PRIDE database (June 2017) 18 . After extensive manual curation of all experimental designs, only untargeted assays that employed phospho-enrichment strategies (for example, metal oxide affinity chromatography and anti-phospho-tyrosine antibodies) were included. Datasets with proteomes from more than one species (such as infections and xenografts) were discarded to prevent cross-species contaminants. Similarly, datasets with major genetic modifications were also discarded for further analysis. For the remaining 110 PRIDE datasets, additional manual curation was required to annotate the biological origin and the search parameters for each raw file. After applying all filters, 6,801 MS raw files remained, corresponding to an accumulated instrument time of 575 d.
All 6,801 MS raw files were jointly searched using MaxQuant 1.6.0.13 (MQ) 19 Andromeda engine 53 against the UniProt Human Reference Proteome (71,567 sequences, accessed May 2017) 54 . These were also supplemented with common laboratory contaminants provided by MQ. On the basis of the labeling strategy or the digestion enzymes, we identified 17 different search parameter groups that were applied to their corresponding raw files. Cysteine carbamidomethylation was set as a fixed modification, while oxidation of methionine, protein N-terminal acetylation and phosphorylation of serine, threonine and tyrosine were set as variable modifications. The minimum peptide length was set to seven amino acids and peptides were allowed to have a maximum of two missed cleavages. All default parameters were also applied to the Orbitrap instruments; the precursor mass tolerance was set to 20 ppm for the first search and 4.5 ppm for the main search. Fragment mass tolerances were set to 20 ppm and 0.5 Da for Fourier transform and ion trap detectors, respectively. All other mass tolerance settings were kept at default values. The search took 60 d in a Dell PowerEdge R730 rack server configured with Intel Xeon CPU E5-2697 v.4 with 2.30 GHz, 64 cores, 256 GB of high-capacity DDR4 memory and a 20-TB fast-access storage drive.
For the identification of modified peptides, MQ default search parameters were used, including 1% PSM FDR, 1% site-level FDR, a minimum Andromeda score of 40 and a minimum delta score of 6. FDR rates were estimated using a target-decoy strategy. In a standard search, the FDR was controlled on the level of PSM and later in the resulting protein groups. In the case of modified peptides, the site decoy fraction can also be used, and when switched on, it is applied after the filtering of PSM but separately to the FDR of protein groups. This filtering step results in a table of PTM sites containing a specified fraction of site decoy hits. The results for phosphorylation sites are contained in the 'Phospho (STY)Sites.txt' table. Notably, because site decoy fraction was applied independently of the protein FDR, phosphorylation sites on peptides that were part of proteins that did not pass protein FDR could still appear in this table. In addition to controlling FDR rates, it is often beneficial to include thresholds that ensure that only post-translationally modified peptide identifications based on spectra of sufficient quality are included. To achieve that, MQ allows the setting of a minimum Andromeda score and a minimum Andromeda delta score for accepting modified peptides. The Andromeda delta score is the difference between the first and second best PSM with a different sequence. Notably, this filtering happens before site-level FDR correction.
To assess the effect of applying false discovery correction at the site level in addition to PSM FDR, two separate searches were performed, one keeping the default 1% site decoy correction and another removing this filtering. Despite both searches being corrected at a 1% PSM FDR, the 1% site FDR search identified 119,809 phosphorylated serines, threonines and tyrosines (121,896 when including the 0.98% of decoys), whereas the search performed without the side-level correction identified 252,189 hits, of which 18.48% were decoys. This difference highlights the importance of controlling FDR rates at relevant steps in the identification pipeline of very large PTM datasets. All processing settings and results, including raw and MQ intermediate files, are available in PRIDE under the accession PXD012174.
Functional annotation of the human phosphoproteome. An extended description of the data sources and methods to functionally annotate phosphosites can be found in Supplementary Note 1. The series of features include information about MS supporting evidence, residue conservation, phosphorylation age reconstruction, consensus motif binding, conditional phosphoregulation, onedimensional structural properties, phosphorylation structural hotspots, structural stability and interfaces, and protein topology annotations.
Phosphosite functional prioritization using machine learning. An MS-derived reference phosphoproteome was defined on the basis of the 119,809 FDRcorrected phosphosites identified in the UniProt reference proteome 54 . To prevent problems with redundant sequences, we focused our prioritization strategy in the 116,258 sites contained in the subset of 21,009 reviewed proteins within the reference proteome. Every site was annotated on the basis of a comprehensive list containing 85 of the aforementioned features (Supplementary Table 2 ). The features were filtered as previously described to remove correlated features. Continuous variables were centered, scaled and normalized using the Yeo-Johnson power transformation and near-zero-variance variables were excluded using the caret package in R. Only complete features were considered, except for SIFT, where a small set of sites from very large proteins required imputation by nearest neighbors. The discrete variables included in the remaining 38 features were transformed into dummy variables, expanding the list to the final 59 features.
To train a machine learning model capable of regressing the functional potential of all phosphosites, we required the phosphoproteome annotated with functional features and a gold-standard set of functional phosphosites. From the MS-identified phosphosites, we defined a gold standard using the 2,638 sites with annotated function in the PSP database (November 2017) 5 with the remaining sites of unknown function set as negatives. A set of regression models was benchmarked using the same strategy. These included random forest, a gradientboosting machine, generalized linear models, regularized linear models, MARS and regression trees. The corresponding R packages for each of the models are described in the caret R wrapper. In all cases, a separate predictor for serine/ threonine and tyrosine residues was built. Nested repeated cross-validation was used to estimate the generalization error of the underlying model and its (hyper) parameter search. In the inside loop, a fivefold cross-validation was performed ten times to tune the parameters. In the outside loop, a threefold cross-validation was repeated five times to quantify the performance of the model using receiver operating characteristic curve analysis. Extensive search grids were defined for every training-validation-testing cycle and parallelized in a high-performance computing environment.
Despite the small differences in the performance of the best methods, the gradient-boosting machine was selected as the final model for the functional score, in part owing to its more harmonic distribution of scores. The parameters displaying the best results were: 500 trees, interaction depth of 9, minimum of ten observations in a node and shrinkage of 0.0405 for serine/threonine and 0.0105 for tyrosine residues. Phosphosite functional scores were derived using these parameters as the median values of all scores obtained by threefold cross-validation repeated 30 times.
Phospho-deficient RANBP1 pulldown assay. A 3×FLAG-tagged fusion of both the WT (UniProt P43487 canonical isoform) and phosphomimetic S60E mutant of RANBP1 was synthesized (GENEWIZ). Lentiviral transduction was used to individually introduce these sequences into HEK293T cells and RANBP1 expression was controlled under a doxycycline-inducible promoter. Cells from three biological replicates each of WT and S60E expression were harvested. Additionally, two biological replicates of control cells not expressing 3×FLAG RANBP1 were harvested, in which no doxycycline was added to the cells. Protein complexes were purified as previously described 55 and analyzed on a Thermo Q-Exactive Plus mass spectrometer. Raw data were searched using MQ 19 , and high-confidence protein-protein interactions were scored using SAINTexpress 56 .
TF activity inference and phosphosite co-regulation. To systematically estimate TF activities and phosphosite co-regulation across a panel of primary tumors, paired basal gene expression and quantitative phosphoproteomic data from the same breast tumors were retrieved from TCGA 35 and CPTAC 34 , respectively. For the 105 breast tumors with matched phosphoproteomics data, raw counts were downloaded from the Gene Expression Omnibus (GSE62944) 57 , normalized, processed into counts per million reads and z-transformed. To infer TF activities from the expression data, 289 good-quality TF regulons (A-C) were retrieved from the OmniPath resource 58 , and an enrichment test per tumor was calculated using the analytic rank-based enrichment analysis method implemented in Viper 59 . The normalized enrichment score was used as an estimate of relative TF activity as described in previous studies 33 . The changes in phosphorylation for TF sites quantified across the 77 samples passing the CPTAC quality control criteria were correlated with their corresponding TF activities.
Effects of genetic variation in human phosphosites.
Variation in natural human populations for 60,706 unrelated individuals was retrieved from the Exome Aggregation Consortium 37 . The variants with their corresponding adjusted allele frequencies were aligned to UniProt positions using the Needleman-Wunsch global alignment implemented in the Biostrings R package. Only variants observed in at least ten counts were considered for further analysis. In cases where multiple alleles mapped to the same exact amino acid substitution, the variant with the highest adjusted frequency was preserved. For comparison purposes, minor allele frequency for phospho-acceptor residues was calculated as the frequency at which the second most common allele occured in the population. To further understand the effects in human variation, a total of 159,633 human clinically relevant variants were retrieved from ClinVar 38 , 1,784 of which matched phospho-acceptor residues. The annotated clinical significances were collapsed into benign, uncertain and pathogenic categories. Finally, the phenotypic consequences of introducing 22,090 missense mutations in 3,022 proteins were retrieved from UniProt 54 . The 4,764 point mutations on phospho-acceptor residues were classified into alanine, phosphomimetic (aspartic or glutamic acid) or 'other' depending on the resulting residue. Because the phenotypic consequences were encoded as free text, an in-house parser was required to annotate the effects as gain of function, loss of function or no effect.
